Pediatric VNS Study Supports Cyberonics’ Focus On Epilepsy Growth Strategy
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics may expand use of its vagus nerve stimulation (VNS) therapy device to children with drug-resistant epilepsy aged 12 and younger, following positive results from a small study conducted by the Children's Hospital at The Cleveland Clinic
You may also be interested in...
Cyberonics Depression Study Yields Benefit In Treatment-Resistant Patients
Cyberonics will present data from its D-04 depression trial in July to determine if venous nerve stimulation (VNS) was responsible for a marked improvement in depression symptoms compared to its D-02 study
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.